Hodgkin Lymphoma: ESMO Clinical Practice Guidelines
Published in 2018 – Ann Oncol (2018) 29 (Suppl 4): iv19–iv29
Authors: D. A. Eichenauer, B. M. P. Aleman, M. André, M. Federico, M. Hutchings, T. Illidge, A. Engert & M. Ladetto, on behalf of the ESMO Guidelines Committee
The 2018 ESMO Clinical Practice Guidelines on Hodgkin lymphoma (HL) are based on results from recent studies and analyses. New recommendations are given regarding treatment with BEACOPPescalated, brentuximab vedotin and anti-PD-1 antibodies. An updated recommendation for regular follow-up comprising screening examinations for malignant and non-malignant late sequelae is included, as therapy-related late effects are frequently observed in HL survivors.
These Clinical Practice Guidelines are endorsed by the European Hematology Association (EHA)